SCHEMBL23728337

SCHEMBL23728337

[CH]=C1Oc2cc(O)ccc2C1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 5/20 0.54
TYR P14679 4/20 0.54
MAOB P27338 4/20 0.54
MEN1 O00255 6/20 0.49
KMT2A Q03164 6/20 0.49
RECQL P46063 2/20 0.49
CISD1 Q9NZ45 2/20 0.49
POLB P06746 1/20 0.49
RAB9A P51151 1/20 0.49
KDM4E B2RXH2 1/20 0.49
PSMD14 O00487 1/20 0.49
AURKA O14965 1/20 0.49
NPC1 O15118 1/20 0.49
DAPK3 O43293 1/20 0.49
JAK2 O60674 1/20 0.49
STK17B O94768 1/20 0.49
ALPL P05186 1/20 0.49
ALPI P09923 1/20 0.49
GAA P10253 1/20 0.49
MAPT P10636 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6984812 0.80 MAOA (0.57) MAOATYRMAOBMEN1KMT2A
SCHEMBL11069101 0.74 MAOA (0.51) MAOATYRMAOBMEN1KMT2A
SCHEMBL29435856 0.70 TYR (1.00) MAOATYRMAOBMEN1KMT2A
SCHEMBL7549906 0.70 TYR (0.51) MAOATYRMAOBMEN1KMT2A
SCHEMBL5707753 0.70 TYR (1.00) MAOATYRMAOBMEN1KMT2A
SCHEMBL30214422 0.70 TYR (1.00) MAOATYRMAOBMEN1KMT2A
SCHEMBL11074407 0.69 TYR (0.61) MAOATYRMAOBMEN1KMT2A
SCHEMBL11070617 0.69 MAOA (0.47) MAOATYRMAOBMEN1KMT2A
SCHEMBL11530855 0.69 TYR (0.47) MAOATYRMAOBMEN1KMT2A
SCHEMBL14259795 0.69 MAOA (0.49) MAOATYRMAOBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 US claimed
WO-2021158573-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
WO-2021158575-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 US disclosed
WO-2021158575-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO disclosed
WO-2021158573-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES FABP2, FABP4, GUSB MAOA 3718/4885TYR 2156/4885MAOB 3174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.